alendronate / Generic mfg. - LARVOL DELTA

A novel approach for discriminating lipophilic bisphosphonate-based pharmaceuticals using a potentiometric array. (PubMed, Anal Methods) - "The lipophilicity of bisphosphonates including ibandronate, clodronate, risedronate, and alendronate was analyzed in both standard and commercial samples. The influence of membrane composition (presence or absence of an anion-exchanger) and PANI deposition conditions (monomer form and/or salt content) on membrane surface properties (lipophilicity and signal stability) was investigated and confirmed using surface-wetting characterization, SEM-EDS mapping and potentiometry. Principal component analysis (PCA) enabled discrimination among the bisphosphonates based on their lipophilicity and revealed distinct contributions of individual ISMs in both standard and commercial samples."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Osteoporosis • Rare Diseases • Rheumatology

Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Endocrinol (Lausanne)) - "The aim of this systematic review and meta-analysis is to evaluate the efficacy and safety of anti-sclerostin antibodies compared to placebo, alendronate, teriparatide and denosumab in the treatment of osteoporosis...The study results demonstrate that anti-sclerostin antibodies can be used to treat postmenopausal osteoporosis. https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD420251103597."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Osteoporosis • Rheumatology

INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE (EBMT 2026) - "All patients had hip involvement with median ARCO stage II; 4 had shoulder and 1 had wrist involvement(median number of joints involved: 2,range:1-4).Twelve AVN patients required vitamin D supplementation at diagnosis of AVN, and 13 received bisphosphonates(alendronate:11, zoledronate:2)...AVN cases received higher starting dose of systemic steroids for acute GVHD(median:2.19 vs 1.19 mg/kg prednisolone equivalents, p=0.016), but there were no differences in steroid therapy duration, steroid-refractoriness, or use of maintenance prednisolone and oral budesonide... Symptomatic AVN incidence among ASCT recipients who developed GVHD was 6.4%, with 57% requiring surgery. Higher pre-ASCT steroid exposure, higher initial steroid dose for acute GVHD, higher CD3+ cell dose, and pre-ASCT vitamin D deficiency were potentially modifiable risk factors for AVN."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Orthopedics • Transplantation

A BONE MARROW-TARGETED NANOMODULATOR AS HISTONE LACTYLATION INHIBITOR FOR REVERSING IMMUNE TOLERANCE OF MULTIPLE MYELOMA (EBMT 2026) - "To enable BM-specific delivery, NanoCURE was coated with hyaluronic acid-alendronate (HA-Ald), allowing it to hijack circulating monocytes/macrophages via HA-CD44 and promote BM homing through alendronate affinity and CXCR4/CXCL12-mediated chemotaxis... Collectively, NanoCURE effectively disrupts the glycolysis–lactate–lactylation cascade and reprograms the BMIM into an immune-reactive niche, offering a potent and targeted strategy to overcome resistance in MM."

IO biomarker • Hematological Malignancies • Multiple Myeloma • CXCL12 • CXCR4 • PKM

Preparation and characterization of decellularized bovine bone as a bioscaffold for bone tissue engineering applications. (PubMed, Iran J Basic Med Sci) - "Osteopontin and osteonectin expression also rose in Cr and Cr/ALN groups, supporting enhanced osteogenic differentiation. Based on in vitro findings, DBB scaffolds demonstrate favorable mechanical and biological properties, and loading the scaffolds with crocin and Alendronate enhanced osteogenic differentiation and matrix mineralization, indicating potential for bone-regeneration applications."

Journal • Hematological Disorders • BGLAP • RUNX2 • SPARC • SPP1

A network meta-analysis of randomized controlled trials evaluating the evidence of pharmacological agents and growth factors in the regeneration of bony defects in chronic periodontitis. (PubMed, BMC Oral Health) - "The study provides clinically relevant evidence supporting the adjunctive use of pharmacologic agents with PRF to optimize regenerative outcomes. Such combinations can improve bone fill and attachment gain, offering predictable benefits for patients with chronic periodontitis."

Journal • Retrospective data • Review • Dental Disorders • Infectious Disease • Periodontitis • Respiratory Syncytial Virus Infections

Bone-Targeting Selenium-Doped Carbon Dot-Based Nanoparticles for Ferroptosis Suppression and Osteogenesis Against Postmenopausal Osteoporosis. (PubMed, Adv Healthc Mater) - "In this study, we have developed bone-targeting selenium-doped carbon dots conjugated with alendronate (ASCDs) with the dual functionality of suppressing ferroptosis and promoting osteogenesis. In vitro, ASCDs mitigated erastin-induced ferroptosis in osteoblasts and bone-marrow mesenchymal stem cells by activating the system Xc--GSH-GPX4 antioxidant pathway, which reduced lipid peroxidation and restored mitochondrial function...Proteomics and biochemical analyses further validated that ASCDs exert therapeutic effects by rescuing GPX4 expression and redox homeostasis. Such dual-functional carbon dots present a targeted strategy to treat PMOP by concurrently inhibiting ferroptosis and restoring bone formation."

Journal • Osteoporosis • Rheumatology • GPX4 • RUNX2

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: University of California, Davis | Not yet recruiting ➔ Recruiting

Enrollment open • Anemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

Evidence on pharmacological agents for treating bony defects in chronic periodontitis: A network meta-analysis. (PubMed, Dent Res J (Isfahan)) - "Effective drugs, such as alendronate, rosuvastatin (RSV), atorvastatin, melatonin, and metformin (MF), have been used as adjuncts to scaling and root planning and require evaluation for their comparative effectiveness in treating bony defects in patients with chronic periodontitis. These findings from the NMA suggest that MF may be an effective option for CAL improvement and BF. Further research is needed to validate these results and optimize treatment strategies for bony defects in chronic periodontitis."

Clinical • Journal • Retrospective data • Review • Dental Disorders • Infectious Disease • Periodontitis • Respiratory Syncytial Virus Infections

Comparison of the Efficacy of Denosumab and Alendronate in Improving Bone Mineral Density in Osteoporosis Patients and High-Risk Populations: A Systematic Review and Meta-Analysis. (PubMed, Clin Drug Investig) - "Denosumab was more effective than alendronate in increasing BMD. However, all the included randomised controlled trials (RCTs) carried a risk of bias, and the patient sample sizes were relatively small. Therefore, further studies with larger sample sizes and better methodological rigor are needed to confirm these findings."

Journal • Retrospective data • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Comparative Molecular Docking, Molecular Dynamics and Adsorption-Release Analysis of Calcium Fructoborate and Alendronate Salts on Hydroxyapatite and Hydroxyapatite-Titanium Implants. (PubMed, Biomedicines) - " The convergence between in silico and adsorption-release data highlights CaFb as the most promising candidate among the tested ligands for long-term functionalization of HAp and HApTi surfaces. Its stronger and more stable binding, higher loading capacity and more sustained release profile suggest that CaFb-coated HApTi implants may provide a favorable basis for future in vitro and in vivo studies aimed at improving osseointegration and mitigating periprosthetic osteolysis, although direct evidence for osteolysis prevention was not obtained in the present work."

Journal • Orthopedics • Osteoporosis

Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis. (PubMed, Front Oncol) - "Seventeen RCTs involving 6,932 postmenopausal patients were included, comparing six interventions: denosumab, alendronate, zoledronic acid, ibandronate, risedronate, and eldecalcitol plus risedronate. Further head-to-head trials are warranted to validate optimal treatment sequences. PROSPERO (CRD420251008444)."

HEOR • Journal • Retrospective data • Review • Breast Cancer • Oncology • Solid Tumor

Bisphosphonates use is associated with increased coronary artery calcification in the general population: The Rotterdam study. (PubMed, Atheroscler Plus) - "Long-term bisphosphonate use is associated with increased arterial calcification, most notably with increased CAC, with a dose-response relationship further strengthening this observation. Large-scale observational studies are encouraged to use advanced causal inference methods to evaluate this long-term association and provide additional evidence to strengthen the causal interpretation."

Journal • Atherosclerosis • Cardiovascular

Evaluation of Osteonecrosis Risk Using Serum C-Terminal Cross-Linked Telopeptide of Type 1 Collagen (CTX-1) Levels in Osteoporotic Patients: Effects of Drug Holidays and Risk Factors. (PubMed, Eurasian J Med) - "Serum CTX-1 levels appeared unaffected by vitamin D. Although the denosumab group exhibited the highest risk of osteonecrosis, the difference compared to zoledronic acid was not statistically significant. These results suggest caution during jaw-related procedures and consideration of drug holidays when necessary.   Cite this article as: Ergül EE, Laçin O, Kılıçaslan HÖ, et al. Evaluation of osteonecrosis risk using serum C-terminal cross-linked telopeptide of type 1 collagen (CTX-1) levels in osteoporotic patients: Effects of drug holidays and risk factors. Eurasian J Med. 2026, 58(1), 1104, doi:10.5152/eurasianjmed.2026.251104."

Journal • Osteoporosis • Rheumatology

Comment on real-world persistence and interpretation of BMD outcomes in denosumab vs. alendronate therapy. (PubMed, J Bone Miner Metab) - No abstract available

Journal • Real-world evidence • Osteoporosis • Rheumatology

Analyzing the effect of osteoporosis drug treatments on femoral strength using 3D-DXA finite elements modelling. (PubMed, J Clin Densitom) - "Osteoporosis treatments included Alendronate (AL, n = 54), Denosumab (DMAB, n = 33), Teriparatide (TPTD, n = 31), and Naïve (NAÏVE, n = 37). Load-bearing capacity increased in both the cortical and trabecular bone of the femoral neck with DMAB and AL, while it only increased in the trabecular bone with TPTD. 3D-DXA FE analysis might help clinicians to better monitor the effects of pharmacological treatments and potentially improve personalised treatment plans for subjects with osteoporosis."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Cellular passages modulate pre-osteoblast responses to bisphosphonate in high-passage cell models. (PubMed, Arch Oral Biol) - "These findings demonstrated differential cellular responses to BPs based on cell passage and interaction between cell passage and ALN. High and late passage cells exhibited distinct sensitivities and behaviors. This underscores the importance of using higher-passage cell models to better mimic aged osteoblasts in vitro when evaluating preclinical studies."

Journal

Engineered 3D Printing Bilayer Scaffold with Spatiotemporal Release of Drug for Synergistic Osteochondral Regeneration. (PubMed, Adv Healthc Mater) - "Here, a 3D-printed bilayer scaffold with spatiotemporal release is presented, which integrates an alendronate sodium-triphenylphosphine (ALN-TPP)-loaded polyacrylic acid/methacrylated flaxseed gum (PAA/FGMA) cartilage layer and an ALN-TPP-loaded PAA/vinyl-modified montmorillonite (vinyl-MMT) bone layer...In a rabbit model with osteochondral defects, the bilayer scaffold facilitates effective formation of hyaline-like cartilage and achieves subchondral bone reconstruction. This work establishes a multifunctional therapeutic platform that can advance the repair of osteochondral defects."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology

Elucidating osteoporosis response signatures in rheumatoid arthritis using explainable machine learning ensembles. (PubMed, BMC Musculoskelet Disord) - "The developed interpretable ML model shows promise for screening osteoporosis risk in patients with RA. Its ability to identify individual risk factors highlights its potential to facilitate personalized prevention and management strategies, pending further validation."

Journal • Immunology • Inflammatory Arthritis • Osteoporosis • Rheumatoid Arthritis • Rheumatology

Clinical and economic impact of deep learning-enhanced opportunistic osteoporosis screening using chest radiographs with and without the osteoporosis self-assessment tool for Asians (OSTA). (PubMed, Osteoporos Int) - "DL-enhanced chest radiographs offer a cost-effective approach for opportunistic osteoporosis screening in Singaporean women aged ≥ 50 years. Combining with OSTA slightly improves efficiency, but DL screening alone is already cost-effective and provides a scalable preventive strategy in real-world healthcare."

HEOR • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A molecular engineered NIR-II fluorescence agent with enhanced radiative and non-radiative decay for precision prostate cancer bone metastasis theranostics. (PubMed, Mater Today Bio) - "Based on these advantages, alendronate-functionalized TQP-TTPA nanoparticles (TQP-TTPA@ALD NPs) are developed for precise and high-resolution NIR-II fluorescence (FLI), photoacoustic (PAI), and phototherml (PTI) trimodal imaging-guided high-efficiency photothermal therapy (PTT) of prostate cancer bone metastases. This work offers a molecular-level design strategy for organic phototheranostics with tunable radiative/non-radiative decay balance, bridging fundamental photophysics and precision cancer theranostics."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Multi-scale biomimetic fusion construction of cerium ion hydrogel-scaffold for promoting osteoporotic bone defect repair. (PubMed, J Orthop Translat) - "Our efficient strategy has developed a multi-scale biomimetic fusion alendronate sodium cerium ion hydrogel scaffold, integrating 3D-printed tricalcium phosphate (TCP) scaffolds, collagen-methacrylate (COMA) hydrogel, and nanoparticles of alendronate sodium cerium ions...We create a hydrogel scaffold that not only offers adequate mechanical support but also possesses a favorable microenvironment for cell growth and contains biological factors promoting osteogenic and angiogenic differentiation. This application represents a pioneering aspect of multi-scale biomimetic hydrogel scaffolds in addressing osteoporotic bone defects, providing a novel direction for the treatment of osteoporotic bone defects."

Journal • Inflammation • Osteoporosis • Rheumatology

Weekly treatment with oral alendronate maintains bone mineral increases gained after one year of romosozumab treatment, in women with chronic spinal cord injury. (PubMed, J Spinal Cord Med) - "There were no appreciable changes in BMD or bone strength at the knee following the alendronate intervention. Overall, one year of treatment with monthly romosozumab followed by one year of treatment with weekly alendronate, significantly increased and maintained bone mineral at the hip, but not the knee, in women with chronic SCI and secondary osteoporosis."

Journal • CNS Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

The effects of spaceflight countermeasures on trabecular bone score (TBS) of the lumbar spine. (PubMed, Arch Osteoporos) - "DXA can detect how various in-flight countermeasures and the length of mission affect the lumbar spine that is enhanced with the addition of TBS."

Journal

Atypical Femoral Fractures Induced by Anti-Resorptive Medications. (PubMed, Curr Osteoporos Rep) - "Key risk factors include advanced age, Asian descent, prolonged Bisphosphonates therapy (exceeding 5 years for alendronate or 3 years for zoledronic acid) without drug holidays, and distinct femoral geometry. Prophylactic surgery benefits high-risk fractures. Future research should elucidate denosumab's mechanisms and develop targeted therapies."

Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology